News
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult ...
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback